D-Index & Metrics Best Publications
Research.com 2022 Best Scientist Award Badge

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Immunology D-index 156 Citations 101,502 353 World Ranking 23 National Ranking 16
Medicine D-index 164 Citations 108,624 417 World Ranking 235 National Ranking 157
Best Scientists D-index 188 Citations 132,652 633 World Ranking 322 National Ranking 217

Research.com Recognitions

Awards & Achievements

2022 - Research.com Best Scientist Award

2020 - Fellow, National Academy of Inventors

2017 - Warren Alpert Foundation Prize For their collective contributions to the pre-clinical foundation and development of immune checkpoint blockade, a novel form of cancer therapy that has transformed the landscape of cancer treatment.

Overview

What is he best known for?

The fields of study he is best known for:

  • Gene
  • Immune system
  • Cancer

His main research concerns Immunology, T cell, Cytotoxic T cell, Cell biology and CD28. As part of the same scientific family, Gordon J. Freeman usually focuses on Immunology, concentrating on Blockade and intersecting with Immunotherapy. His T cell study typically links adjacent topics like Molecular biology.

Gordon J. Freeman focuses mostly in the field of Cytotoxic T cell, narrowing it down to matters related to Cancer research and, in some cases, Immune checkpoint, Stem cell and PD-L1. His Cell biology study incorporates themes from Inducible T-Cell Co-Stimulator Protein, Interleukin 2, Receptor, Cytokine and Programmed Cell Death 1 Ligand 2 Protein. His CD28 study combines topics in areas such as Jurkat cells, Naive B cell, Cellular differentiation and Cell–cell interaction.

His most cited work include:

  • Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. (3499 citations)
  • PD-1 and its ligands in tolerance and immunity. (3226 citations)
  • Restoring function in exhausted CD8 T cells during chronic viral infection (2941 citations)

What are the main themes of his work throughout his whole career to date?

Immunology, T cell, Immune system, Cell biology and Cancer research are his primary areas of study. His work carried out in the field of Immunology brings together such families of science as Blockade and Virology. The study incorporates disciplines such as Cytotoxic T cell, Nucleic acid and Molecular biology in addition to T cell.

The various areas that Gordon J. Freeman examines in his Immune system study include Cell and Antibody. He has researched Cell biology in several fields, including Receptor, Ligand, Programmed Cell Death 1 Ligand 2 Protein and Cytokine. His Cancer research research focuses on Immunotherapy and how it connects with Oncology.

He most often published in these fields:

  • Immunology (38.44%)
  • T cell (35.49%)
  • Immune system (26.80%)

What were the highlights of his more recent work (between 2018-2021)?

  • Cancer research (23.71%)
  • Immunotherapy (12.37%)
  • Immune system (26.80%)

In recent papers he was focusing on the following fields of study:

Gordon J. Freeman spends much of his time researching Cancer research, Immunotherapy, Immune system, Blockade and Immune checkpoint. His Cancer research research incorporates themes from Cancer, Antibody, CD8 and T cell. Gordon J. Freeman applies his multidisciplinary studies on T cell and Dimer in his research.

Gordon J. Freeman has included themes like Cell, Lung cancer, Leukemia and Lymphoma in his Immune system study. The concepts of his Blockade study are interwoven with issues in Phenotype, Ovalbumin, Immunology, Chronic infection and Cytotoxic T cell. Gordon J. Freeman has included themes like CD28, Inhibitory postsynaptic potential and Cell biology in his Receptor study.

Between 2018 and 2021, his most popular works were:

  • Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy. (132 citations)
  • The importance of exosomal PDL1 in tumour immune evasion (81 citations)
  • Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1+ Stem-like CD8+ T Cells during Chronic Infection. (79 citations)

In his most recent research, the most cited papers focused on:

  • Gene
  • Cancer
  • Immune system

Gordon J. Freeman mainly investigates Cancer research, Immunotherapy, Immune system, CD8 and Immune checkpoint. Gordon J. Freeman has researched Immunotherapy in several fields, including Tumor microenvironment, Antibody and Oncology. His Immune system study is mostly concerned with T cell and PD-L1.

His work carried out in the field of T cell brings together such families of science as Cyclin-dependent kinase, Biophysics and Cancer immunotherapy. His CD8 study combines topics in areas such as Cytotoxic T cell, Carcinoma and Clear cell renal cell carcinoma. His work is dedicated to discovering how Immune checkpoint, Cell biology are connected with Viral disease, Vesicle and Flow cytometry and other disciplines.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.

Gordon J. Freeman;Andrew J. Long;Yoshiko Iwai;Karen Bourque.
Journal of Experimental Medicine (2000)

4627 Citations

PD-1 and its ligands in tolerance and immunity.

Mary E. Keir;Manish J. Butte;Gordon J. Freeman;Arlene H. Sharpe.
Annual Review of Immunology (2008)

4435 Citations

Restoring function in exhausted CD8 T cells during chronic viral infection

Daniel L. Barber;E. John Wherry;David Masopust;Baogong Zhu.
Nature (2006)

3738 Citations

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Stephen M. Ansell;Alexander M. Lesokhin;Alexander M. Lesokhin;Ivan Borrello;Ahmad Halwani.
The New England Journal of Medicine (2015)

2980 Citations

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

Yvette Latchman;Clive R. Wood;Tatyana Chernova;Divya Chaudhary.
Nature Immunology (2001)

2801 Citations

THE B7 FAMILY REVISITED

Rebecca J. Greenwald;Gordon J. Freeman;Arlene H. Sharpe.
Annual Review of Immunology (2005)

2709 Citations

PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression

Cheryl L Day;Daniel E Kaufmann;Photini Kiepiela;Julia A Brown.
Nature (2006)

2583 Citations

CD4+CD25high Regulatory Cells in Human Peripheral Blood

Clare Baecher-Allan;Julia A. Brown;Gordon J. Freeman;David A. Hafler.
Journal of Immunology (2001)

2434 Citations

CTLA-4 can function as a negative regulator of T cell activation

Theresa L. Walunas;Deborah J. Lenschow;Christina Y. Bakker;Peter S. Linsley.
Immunity (1994)

2196 Citations

The B7–CD28 superfamily

Arlene H Sharpe;Gordon J Freeman.
Nature Reviews Immunology (2002)

2122 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Gordon J. Freeman

Arlene H. Sharpe

Arlene H. Sharpe

Harvard University

Publications: 226

Hideo Yagita

Hideo Yagita

Juntendo University

Publications: 222

Lieping Chen

Lieping Chen

Yale University

Publications: 206

Bruce R. Blazar

Bruce R. Blazar

University of Minnesota

Publications: 163

Vijay K. Kuchroo

Vijay K. Kuchroo

Harvard University

Publications: 146

James P. Allison

James P. Allison

The University of Texas MD Anderson Cancer Center

Publications: 137

Mohamed H. Sayegh

Mohamed H. Sayegh

Brigham and Women's Hospital

Publications: 125

Miyuki Azuma

Miyuki Azuma

Tokyo Medical and Dental University

Publications: 122

Jedd D. Wolchok

Jedd D. Wolchok

Memorial Sloan Kettering Cancer Center

Publications: 122

Carl H. June

Carl H. June

University of Pennsylvania

Publications: 118

Jeffrey A. Bluestone

Jeffrey A. Bluestone

University of California, San Francisco

Publications: 109

David A. Hafler

David A. Hafler

Yale University

Publications: 102

E. John Wherry

E. John Wherry

University of Pennsylvania

Publications: 102

Bruce D. Walker

Bruce D. Walker

Harvard University

Publications: 101

Richard A. Flavell

Richard A. Flavell

Yale University

Publications: 92

Lee M. Nadler

Lee M. Nadler

Harvard University

Publications: 91

Trending Scientists

John Fox

John Fox

University of Oxford

Jose Emmanuel Ramirez-Marquez

Jose Emmanuel Ramirez-Marquez

Stevens Institute of Technology

Giorgio Franceschetti

Giorgio Franceschetti

University of Naples Federico II

Norman J. Zabusky

Norman J. Zabusky

Rutgers, The State University of New Jersey

Randolph V. Lewis

Randolph V. Lewis

Utah State University

Carl R. Kannewurf

Carl R. Kannewurf

Northwestern University

Michael Boutros

Michael Boutros

German Cancer Research Center

Pascal Dollé

Pascal Dollé

Inserm : Institut national de la santé et de la recherche médicale

Oriol Bachs

Oriol Bachs

University of Barcelona

Dimitra Voutsa

Dimitra Voutsa

Aristotle University of Thessaloniki

Sagar V. Krupa

Sagar V. Krupa

University of Minnesota

Takeo Watanabe

Takeo Watanabe

Brown University

Susumu Sato

Susumu Sato

National Institutes of Health

Francisco Ruiz-Cabello

Francisco Ruiz-Cabello

University of Granada

John H. Falk

John H. Falk

Oregon State University

Something went wrong. Please try again later.